sarcoma
FDA Clears Medigene's IND for TCR-T Therapy in Certain Advanced Solid Tumors
The firm plans to launch a Phase I trial for the autologous TCR-T cell therapy by year-end if additional funding comes through.
'The Lead That Starts the Avalanche': Second Solid Tumor Cell Therapy Approval Energizes the Field
Premium
Adaptimmune's recent Tecelra approval further bolsters confidence in the feasibility of commercial approval for autologous cell therapies in solid tumors.
FDA Approves Adaptimmune's TCR Therapy Tecelra for Certain Synovial Sarcoma Patients
The accelerated approval marks the first time the FDA has approved an engineered autologous cell therapy for a solid tumor indication.
First Ascent is hoping to begin a randomized trial evaluating its functional precision medicine platform after positive results.
Replay, MD Anderson Venture Syena Bets on NK Cells to Bring TCR Therapy to Solid, Blood Cancers
Premium
After launching the first therapy, NY-ESO-1 TCR/IL-15 NK, in a multiple myeloma trial earlier this month, Syena is exploring the approach in new targets and tumor types.
Jun 29, 2022
May 25, 2022
Oct 8, 2021